Profil
Marc Dechamps is Chief Executive Officer at Bioxodes SA since 2022.
Mr. Dechamps is Independent Director at OSE Immunotherapeutics SA since 2024.
Formerly, Mr. Dechamps was Co-Managing Director at Catalent Gosselies PS SA. Mr. Dechamps was Director & Head-Business Development at eTheRNA immunotherapies NV.
Aktive Positionen von Marc Dechamps
| Unternehmen | Position | Beginn |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Direktor/Vorstandsmitglied | 19.06.2024 |
Bioxodes SA
Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Vorstandsvorsitzender | 01.10.2022 |
Ehemalige bekannte Positionen von Marc Dechamps
| Unternehmen | Position | Ende |
|---|---|---|
Delphi Genetics SA
Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Vorstandsvorsitzender | 01.07.2017 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Delphi Genetics SA
Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Health Technology |
Bioxodes SA
Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Health Technology |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases | Health Technology |
















